TAPUR, NCT02693535: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer |
|
|
| Recruiting | 2 | 3791 | US | Palbociclib, Ibrance, Sunitinib, Sutent, Temsirolimus, Torisel, Trastuzumab and Pertuzumab, Herceptin and Perjeta, Vemurafenib and Cobimetinib, Zelboraf and Cotellic, Regorafenib, Stivarga, Olaparib, Lynparza, Pembrolizumab, Keytruda, Nivolumab and Ipilimumab, Opdivo and Yervoy, Abemaciclib, Verzenio, Talazoparib, Talzenna, Atezolizumab and PHESGO, Tecentriq and PHESGO, Atezolizumab and Talazoparib, Tecentriq and Talzenna, Entrectinib, Rozlytrek, Larotrectinib, Vitrakvi, Tucatinib plus Trastuzumab Subcutaneous (SC), Tukysa and Herceptin Hylecta, Futibatinib, Lytgobi | American Society of Clinical Oncology, AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, Pfizer, Boehringer Ingelheim, Seagen Inc., Taiho Oncology, Inc. | Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors | 06/26 | 06/27 | | |
| Enrolling by invitation | 1/2 | 36 | US | SV-BR-1-GM, Low dose cyclophosphamide, Cytoxan, Interferon Inoculation, retifanlimab, INCMGA00012 | BriaCell Therapeutics Corporation, LumaBridge | Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic | 11/25 | 11/28 | | |
